Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
9.65
+0.04 (0.36%)
Sep 18, 2025, 11:34 AM EDT - Market open
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $724.51M in the quarter ending June 30, 2025, with 3.24% growth. This brings the company's revenue in the last twelve months to $2.85B, up 9.81% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.85B
Revenue Growth
+9.81%
P/S Ratio
1.05
Revenue / Employee
$343,725
Employees
8,300
Market Cap
3.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AMRX News
- 7 days ago - Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution - GlobeNewsWire
- 7 days ago - Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing - Seeking Alpha
- 13 days ago - Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - GlobeNewsWire
- 6 weeks ago - Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico - GlobeNewsWire
- 6 weeks ago - Amneal Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 - GlobeNewsWire
- 2 months ago - Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - GlobeNewsWire